Medical Appliances Stocks Under Scanner -- Neovasc, Hologic, Edwards Lifesciences, and Sunshine Heart

Friday, March 24, 2017 Heart Disease News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 24, 2017 /PRNewswire/ --

Today Stock-Callers.com have issued research reports on four Medical Appliances

and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences Corp. (NYSE: EW), and Sunshine Heart Inc. (NASDAQ: SSH). These companies are part of the Healthcare sector, which gave back most of its prior
gains on Thursday, March 23rd, 2017, with the NYSE Health Care Index declining 0.2% in the afternoon, while shares of health care companies in the S&P 500 were down about 0.4% as a group. You can access our complimentary research reports on these stocks now at:

http://stock-callers.com/registration

Neovasc  

Shares in Richmond, Canada headquartered Neovasc Inc. saw a slight drop of 0.59%, ending Thursday's trading session at $1.68. The stock recorded a trading volume of 862,933 shares. The Company's shares have surged 22.63% in the last one month. The stock is trading 13.15% and 77.36% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have a Relative Strength Index (RSI) of 57.20. Visit us today and download your complete report on NVCN for free at:

http://stock-callers.com/registration/?symbol=NVCN

Hologic  

Marlborough, Massachusetts headquartered Hologic Inc.'s stock rose 0.33%, closing the day at $42.23 with a total trading volume of 1.27 million shares. The Company's shares have advanced 4.87% in the past month, 5.50% in the previous three months, and 5.26% since the start of this year. The stock is trading 4.01% and 9.85% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 60.88.

On March 22nd, 2017, Hologic announced that it has completed the acquisition of Cynosure, Inc. for $66 per share in cash. Hologic intends to discuss the financial implications of the acquisition on Wednesday, May 10th, 2017, when the Company reports its financial results for Q2 FY17, and provides updated financial guidance. The complimentary research report on HOLX can be accessed at:

http://stock-callers.com/registration/?symbol=HOLX

Edwards Lifesciences  

On Thursday, shares in Irvine, California headquartered Edwards Lifesciences Corp. recorded a trading volume of 1.67 million shares. The stock ended the day 0.89% higher at $94.30. The Company's shares have advanced 2.27% in the past month, 3.77% in the previous three months, and 0.64% on an YTD basis. The stock is trading above its 50-day moving average by 0.82%. Furthermore, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 54.22.

On March 09th, 2017, Edwards Lifesciences announced that a district court in Düsseldorf, Germany ruled that Boston Scientific's Lotus valve infringes one of Edwards' patents for transcatheter aortic valves, but does not infringe a second. The court also ruled that the Edwards SAPIEN 3 valve infringes two of Boston Scientific's patents for outer seals of transcatheter heart valves.  Edwards will promptly request an appeal. Register for free on Stock-Callers.com and download the PDF research report on EW at:

http://stock-callers.com/registration/?symbol=EW

Sunshine Heart  

Eden Prairie, Minnesota headquartered Sunshine Heart Inc.'s stock dropped 2.24%, finishing yesterday's session at $2.18. A total volume of 10.06 million shares was traded, which was above their three months average volume of 521,190 shares. The Company's shares have skyrocketed 379.12% in the previous three months and 522.86% on an YTD basis. The stock is trading above its 200-day moving average by 39.89%. Additionally, shares of Sunshine Heart, which develops technologies for cardiac and coronary diseases, have an RSI of 19.14.

On March 02nd, 2017, Sunshine Heart announced its financial results for Q4 2016 ended December 31st, 2016. During the quarter, the Company reduced total costs and expenses by 40%, and operating cash utilization by 43% from same quarter last year. Sunshine Heart also completed a registered direct offering and a private placement of convertible preferred shares and stock warrants during the quarter for total gross proceeds of approximately $3.6 million. Get free access to your research report on SSH at:

http://stock-callers.com/registration/?symbol=SSH

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook